RAPP
VENTE TOTALE: 78 630 titres (~3 706 350,41 $ US)
- Insiders
- Ceesay Abraham
- Total bought
- —
- Total sold
- $3,706,350
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-31
Despite a strong liquidity score (85), RAPP's near-zero fundamental trend score (15) reflects a non-viable business model with zero revenue, persistent operating losses, and no path to positive cash flow.
The first sentence of the analysis written for RAPP on 2026-08-31 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 26.173 | 35.337 | 17.139 | 18.802 | |
| Quick Ratio | 26.173 | 35.337 | 17.139 | 18.802 | |
| Solvency Ratio | -3.977 | -8.149 | -0.192 | -0.879 | |
| Cash Ratio | 2.764 | 6.479 | 7.971 | 18.737 | |
| Price To Earnings Ratio | -10.608 | -4.693 | -21.895 | -71.724 | |
| Price To Earnings Growth Ratio | 0.436 | -0.016 | -0.096 | 0.000 | |
| Forward Price To Earnings Growth Ratio | 0.436 | -0.016 | -0.096 | 0.000 | |
| Price To Earnings Diluted Ratio | -10.608 | -4.693 | -21.895 | -71.724 | |
| Price To Earnings Diluted Growth Ratio | 0.436 | -0.016 | -0.096 | 0.000 | |
| Price To Book Ratio | 2.941 | 1.205 | -14.670 | 21.453 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -16.180 | -5.472 | -13.049 | -118.671 | |
| Price To Operating Cash Flow Ratio | -16.294 | -5.675 | -13.835 | -129.067 | |
| Debt To Assets Ratio | 0.022 | 0.005 | 0.014 | 0.330 | |
| Debt To Equity Ratio | 0.024 | 0.005 | -0.084 | 0.535 | |
| Debt To Capital Ratio | 0.023 | 0.005 | -0.091 | 0.349 | |
| Long Term Debt To Capital Ratio | 0.018 | 0.000 | 0.000 | 0.349 | |
| Financial Leverage Ratio | 1.057 | 1.031 | -6.063 | 1.620 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.592 | -7.395 | -3.088 | -1.949 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | 1.037 | 1.060 | 1.088 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -36.323 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | -36.375 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -7.617 | -43.921 | -12.666 | -0.311 | |
| Capital Expenditure Coverage Ratio | -142.002 | -26.956 | -16.614 | -11.415 | |
| Dividend Paid And Capex Coverage Ratio | -142.002 | -26.956 | -16.614 | -11.415 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -11.155 | -3.802 | -8.540 | -38.419 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 26.173 | ▼-9.165 | ▲1.810 |
| Quick Ratio | 26.173 | ▼-9.165 | ▲1.810 |
| Solvency Ratio | -3.977 | ▲4.173 | ▼-0.677 |
| Cash Ratio | 2.764 | ▼-3.716 | ▼-6.224 |
| Price To Earnings Ratio | -10.608 | ▼-5.915 | ▲16.622 |
| Price To Earnings Growth Ratio | 0.436 | ▲0.452 | ▲0.355 |
| Forward Price To Earnings Growth Ratio | 0.436 | ▲0.452 | ▲0.355 |
| Price To Earnings Diluted Ratio | -10.608 | ▼-5.915 | ▲16.622 |
| Price To Earnings Diluted Growth Ratio | 0.436 | ▲0.452 | ▲0.355 |
| Price To Book Ratio | 2.941 | ▲1.736 | ▲0.209 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -16.180 | ▼-10.709 | ▲22.163 |
| Price To Operating Cash Flow Ratio | -16.294 | ▼-10.619 | ▲24.923 |
| Debt To Assets Ratio | 0.022 | ▲0.018 | ▼-0.070 |
| Debt To Equity Ratio | 0.024 | ▲0.019 | ▼-0.096 |
| Debt To Capital Ratio | 0.023 | ▲0.018 | ▼-0.048 |
| Long Term Debt To Capital Ratio | 0.018 | ▲0.018 | ▼-0.074 |
| Financial Leverage Ratio | 1.057 | ▲0.026 | ▲1.646 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.592 | ▲2.803 | ▼-0.336 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.007 | ▼-0.030 | ▼-0.041 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲9.081 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲9.094 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -7.617 | ▲36.304 | ▲8.512 |
| Capital Expenditure Coverage Ratio | -142.002 | ▼-115.046 | ▼-92.755 |
| Dividend Paid And Capex Coverage Ratio | -142.002 | ▼-115.046 | ▼-92.755 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -11.155 | ▼-7.353 | ▲4.324 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Market cap | $1.43B | $367.9M | $376.0M | $418.4M | |
| Enterprise value | $1.38B | $312.6M | $308.0M | $397.7M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -15.82x | -4.82x | -11.33x | -122.67x | |
| EV / Free cash flow | -15.71x | -4.65x | -10.69x | -112.79x | |
| EV / EBITDA | -11.15x | -3.80x | -8.54x | -38.42x | |
| Net debt / EBITDA | 0.33x | 0.67x | 1.89x | 2.00x | |
| Current ratio | 26.17x | 35.34x | 17.14x | 18.80x | |
| Income quality | 0.79x | 0.83x | 0.78x | 0.30x | |
| Graham net-net | $10 | $14 | -$2 | $1 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 89.1% | 94.3% | 96.1% | 102.7% | |
| Working capital | $479.5M | $301.0M | $142.1M | $29.6M | |
| Invested capital | $492.4M | $306.0M | $146.1M | $29.9M | |
| Return on assets | -21.8% | -24.9% | -22.4% | -33.7% | |
| Operating ROA | -30.2% | -35.3% | -38.7% | 0.0% | |
| Return on tangible assets | -21.8% | -24.9% | -22.4% | -33.7% | |
| Return on equity | -23.0% | -25.6% | 135.7% | -54.6% | |
| Return on invested capital | -25.2% | -27.1% | -24.6% | -34.6% | |
| Return on capital employed | -25.4% | -27.1% | -24.7% | -34.6% | |
| Earnings yield | -7.8% | -21.3% | -9.3% | -2.5% | |
| Free cash flow yield | -6.2% | -18.3% | -7.7% | -0.8% | |
| Capex / Op. cash flow | -0.7% | -3.7% | -6.0% | -8.8% | |
| Capex / Depreciation | 60.6% | 286.7% | 1460.7% | 1735.5% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 35283d | |
| Operating cycle | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | -35283d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+287.4%EV / Sales n/aEV / EBITDA ▼-193.4%EV / Op. cash flow ▼-11.002Earnings yield ▲+0.135
Profitability
Return on equity ▲+0.026Return on assets ▲+0.031Return on invested capital ▲+0.018Return on capital employed ▲+0.018Operating ROA ▲+0.051Income quality ▼-0.043Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▼-9.165Net debt / EBITDA ▼-0.341Working capital ▲+178477000.000Invested capital ▲+186391000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+240.6%EV / Sales n/aEV / EBITDA ▲+71.0%EV / Op. cash flow ▲+106.851Earnings yield ▼-0.053
Profitability
Return on equity ▲+0.316Return on assets ▲+0.119Return on invested capital ▲+0.094Return on capital employed ▲+0.093Operating ROA n/aIncome quality ▲+0.480Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-35283.333Operating cycle n/aCash conversion cycle ▲+35283.333Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+7.370Net debt / EBITDA ▼-1.670Working capital ▲+449907000.000Invested capital ▲+462457000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-08 Legal & General Group Plc Acquires Shares of 22,555 Rapport Therapeutics, Inc. $RAPP Legal and General Group Plc acquired a new stake in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 22,555 shares of the company''s stock, valued at approximately $940,000. Several other hedge
- 2026-09-02 Rapport Therapeutics to Participate in Upcoming Investor Conferences BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.
- 2026-08-30 Deutsche Bank AG Takes $1.34 Million Position in Rapport Therapeutics, Inc. $RAPP Deutsche Bank AG acquired a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 32,212 shares of the company''s stock, valued at approximately $1,342,000. Deutsche Bank AG owned about
- 2026-08-26 Algert Global LLC Purchases Shares of 223,822 Rapport Therapeutics, Inc. $RAPP Algert Global LLC purchased a new position in shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP) during the undefined quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 223,822 shares of the company''s stock, valued at approximately $9,327,000. Algert Global LLC owned about 0.47% of Rapport Therapeutics
- 2026-08-25 Rapport Therapeutics (NASDAQ:RAPP) Sets New 12-Month High – Time to Buy? Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) shares reached a new 52-week high during mid-day trading on Tuesday. The company traded as high as $50.34 and last traded at $49.33, with a volume of 365422 shares changing hands. The stock had previously closed at $48.24. Analyst Upgrades and Downgrades A number of research
- 2026-08-24 Rapport Therapeutics to Host Virtual KOL Event on the Unmet Need in Bipolar Mania and the RAP-219 Clinical Program BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here.
- 2026-08-21 Rapport Therapeutics: A 22-Day Half-Life Creates A Differentiated Epilepsy Franchise Rapport Therapeutics is differentiated by RAP-219''s neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials, with $436.1M in cash expected to last into 2H 2029, but it will likely need more capital before commercial launch. RAP-219''s long half-life offers a ''forgiveness'' advantage for missed doses, but regulatory scrutiny is expected regarding safety during prolonged exposure.
- 2026-08-05 Rapport Therapeutics Reports Second Quarter 2026 Financials and Provides Business Update RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending June 30, 2026, and highlighted continued progress across the RAP-219 development program and pipeline. "We remain focused on disciplined execution as we deliver against several important catalysts this year," said Abraham N.
- 2026-07-18 Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86 Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy
- 2026-07-12 What Does the Sale of Rapport Therapeutics Stock Worth Over $400,000 by the Chief Operating Officer Mean for Investors? COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault''s direct holdings, reducing her position from 159,914 to 149,914 shares.